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Many pathways to muscular 
dystrophy
The mechanism whereby a contractile mul-
tinucleated skeletal muscle fiber is linked 
to the basement membrane (BM) that 
ensheaths it represents a paradigm for our 
understanding of BM assembly and inter-
actions between the cell and extracellular 
matrix in the context of human pathobiol-
ogy. Multiple matrix proteins, cell-surface 
receptors, transmembrane accessory pro-
teins, cytoskeletal linker proteins, and gly-
cosylating enzymes are required for the 
establishment and maintenance of the large, 
integrated complex that tightly links the 
myofiber cytoskeleton to the sarcolemma 
(plasma membrane) and the sarcolemma to 
the skeletal muscle BM (1). Genetic defects 
that alter the expression, structure, or func-
tion of these proteins cause a devastating 
class of diseases, the muscular dystrophies.
Muscular dystrophies are characterized 
by the progressive degeneration and weak-
ness of skeletal muscle that includes muscle 
fiber necrosis, regeneration, and fibrosis 
(2). The severity and rate of progression of 
muscular dystrophy can vary dramatically, 
from congenital forms to the more common 
delayed-onset form known as Duchenne 
muscular dystrophy (3). From a cell biolog-
ical perspective, muscular dystrophies with 
a genetic basis can be divided into types that 
correspond roughly to the site of the protein 
or protein complex that is affected by muta-
tion. Mutations that affect the muscle BM 
cause congenital muscular dystrophy; those 
that affect the cytoskeletal protein dystro-
phin cause Duchenne and Becker muscular 
dystrophy; and those that affect transmem-
brane proteins called sarcoglycans cause 
limb-girdle muscular dystrophy (3). Inter-
estingly, mutations that impact the enzymes 
responsible for glycosylation of dystrogly-
can cause the dystroglycanopathies, which 
manifest as muscular dystrophies with vari-
able degrees of severity and timing of onset, 
as well as variable CNS and eye defects 
(4). Dystroglycan serves as the functional 
centerpiece of the dystrophin-glycoprotein 
complex that links the cytoskeleton to the 
BM and, therefore, plays a crucial role in 
maintaining skeletal muscle health (5).
Laminin and the basement 
membrane
Like all BMs, the skeletal muscle fiber BM 
contains specific isoforms from four major 
matrix protein families: laminins, type IV 
collagens, nidogens, and heparan sulfate 
proteoglycans. Laminins are large hetero-
trimeric glycoproteins composed of one 
α, one β, and one γ chain (6). The major 
laminin isoform of skeletal muscle BM 
is laminin α2β1γ1 (Lm211; Figure 1, left), 
while a structurally and functionally dif-
ferent isoform, laminin α5β2γ1, is found at 
the neuromuscular junction (7). Lm211 is 
a cruciform macromolecule that can self- 
polymerize in vitro to form a network via 
the formation of intermolecular ternary 
complexes involving the laminin N-termi-
nal (LN) domain of each of the three chains 
(8). The unique C-terminus of the α2 chain, 
called the laminin globular (LG) domain, 
binds to receptors on the surface of the 
myofiber, including α-dystroglycan and 
integrin α7β1 (1). The binding of laminin 
to its receptors as muscle forms is thought 
to have a dual purpose: a) initiation of BM 
formation by concentrating the laminin at 
the cell surface above a critical concentra-
tion that promotes polymerization; and b) 
sending a signal to the cell (9). Upon mat-
uration, laminin binding to its receptors 
links the muscle fiber to the BM, into which 
the laminin has become deeply integrated 
via direct and indirect interactions with 
nidogen, collagen IV, and proteoglycans.
Mutations in the laminin α2–encoding 
gene (LAMA2) cause congenital muscular 
dystrophy. Mutations that prevent produc-
tion of the protein typically (though not 
always) cause more severe disease than do 
missense mutations, internal deletions, or 
mutations that reduce Lm211 protein lev-
els (1) (Figure 1, middle). The existence of 
several naturally occurring and engineered 
mouse models with Lama2 mutations with 
features of human congenital muscular dys-
trophy have been instrumental for investi-
gating pathogenic mechanisms and poten-
tial treatments for both severe and milder 
forms of the disease (10).
Biochemistry and protein therapy
The current work by McKee et al. in this 
issue (11) and previous studies have exploit-
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Muscular dystrophies result from a defect in the linkage between the muscle 
fiber cytoskeleton and the basement membrane (BM). Congenital muscular 
dystrophy type MDC1A is caused by mutations in laminin α2 that either 
reduce its expression or impair its ability to polymerize within the muscle 
fiber BM. Defects in this BM lead to muscle fiber damage from the force 
of contraction. In this issue of the JCI, McKee and colleagues use a laminin 
polymerization–competent, designer chimeric BM protein in vivo to restore 
function of a polymerization-defective laminin, leading to normalized 
muscle structure and strength in a mouse model of MDC1A. Delivery of such 
a protein to patients could ameliorate many aspects of their disease.
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nin network, albeit an aberrant network, 
to dystroglycan, which is likely the major 
mechanism of disease attenuation (14, 15).
Patients who harbor mutations that 
only affect the LMα2 LN domain have 
mild phenotypes compared with those 
with mutations that result in total loss of 
LMα2 (16), similar to missense mutations 
in the LMβ2 LN domain that affect the kid-
ney glomerular BM of Pierson syndrome 
spectrum patients (17). On the basis of bio-
chemical studies, LN domain mutations in 
LMβ2 and LMα2 are predicted to confer 
some degree of laminin polymerization 
defects. For LMα2, these are collective-
ly modeled by dy2J/dy2J mice that lack the 
LMα2 LN domain; but, unlike dyw/dyw 
mice, dy2J/dy2J mice show only a modest 
decrease in LMα2 protein levels. McKee et 
al. exploited the laminin-nidogen-collagen 
linkage to explore the therapeutic efficacy 
of a chimeric fusion protein, αLNNd, via 
transgenic expression in skeletal muscle of 
dy2J/dy2J mice.
The αLNNd protein is composed of 
the LMα1 LN and LEa1-4 domains fused 
to the G2-G3 portions of nidogen, there-
by replacing the nidogen G1 domain and 
short segment that connects G1 to the 
G2-G3 segment with the LMα1 N-termi-
nus. The nidogen portion binds to LMγ1 
LE3b via the G3 domain and to the colla-
gen type IV network via the G2 domain, 
thereby preserving the laminin-collagen 
linkage. Biochemical studies and natu-
rally existing laminin heterotrimer com-
binations (Lm111, Lm211) prove that both 
LMα1 and LMα2 LN domains facilitate 
polymerization through interactions with 
LMβ1 and LMγ1 LN domains. Addition-
ally, both overexpression and exogenous 
provision of Lm111 can ameliorate muscu-
lar dystrophy in Lama2-mutant mice (18, 
19). Thus, the LMα1 LN domain of αLNNd 
readily substitutes for the missing LMα2 
LN domain both in vivo and in vitro (11). 
This chimeric protein corrects the polym-
erization defect in dy2J/dy2J mice (Figure 
1, right) (and should presumably do the 
same in LMα2 polymerization–defective 
patients), thereby reinforcing the concept 
that laminin polymerization is critical for 
maintaining BM integrity. Moreover, like 
the effects of the mini-agrin protein in the 
dyw/dyw and dy3K/dy3K models, the αLNNd 
chimera restored muscle performance in 
dy2J/dy2J animals to a level similar to that 
LMα2 is either truncated and expressed at 
very low levels (dyw/dyw mice) or complete-
ly missing (dy3K/dy3K mice). These mice and 
patients who lack LMα2 exhibit increased 
LMα4- and LMα5-containing trimers, 
but decreased α-dystroglycan expression. 
Although these laminins have poor muscle- 
specific receptor binding, and LMα4 lacks 
the LN domain required for polymeriza-
tion, Ruegg and colleagues hypothesized 
that a mini-agrin protein containing only 
the laminin- and dystroglycan-binding 
domains might both stabilize the laminin 
network and restore dystroglycan levels. 
Collectively, dy3K/ dy3K and dyw/dyw mice 
expressing mini-agrin in skeletal muscle via 
a transgene exhibited a marked increase in 
muscle function and lifespan and improved 
BM morphology, with increased incorpora-
tion of the polymerization-capable LMα5. 
In this scenario, mini-agrin links the lami-
ed the intermolecular interactions among 
BM proteins and their cognate receptors 
that have been deciphered through decades 
of basic science research. In addition to 
laminin-receptor interactions, laminins are 
secondarily and indirectly linked to cell- 
surface receptors by the heparan sulfate 
proteoglycan agrin, which binds to the LMγ1 
coiled-coil region via its N-terminal agrin 
domain as well as to dystroglycan and inte-
grins via its C-terminal LG-like domains 
(12). Furthermore, the laminin network is 
linked to the type IV collagen network by 
nidogen, which binds to the short arm LE3b 
segment of LMγ1 via nidogen’s G3 domain 
and to a region in collagen IV near the C- 
terminal noncollagenous 1 (NC1) domain 
via nidogen’s G2 domain (13).
Previously, research teams led by Ruegg 
tested a molecular therapy in severe forms 
of congenital muscular dystrophy, in which 
Figure 1. A designer chimeric polypeptide restores function of defective laminin. Lm211 is a hetero-
trimeric glycoprotein consisting of one α2-, one β1-, and one γ1-subunit that is an essential extracel-
lular matrix component of the skeletal muscle fiber BM. WT Lm211 readily polymerizes and becomes 
integrated into the BM and serves to link the muscle fiber to the BM via receptor binding. Mutations 
in the gene encoding the laminin α2-subunit cause a congenital muscular dystrophy due to absent or 
defective Lm211. The mutant Lm211 present in dy2J/dy2J mice has a truncated laminin α2 that is unable 
to polymerize. The polymerization defect results in disruption of the BM, leading to loss of BM integri-
ty and reduced muscle function. In this issue, McKee and colleagues developed a chimeric polypeptide 
(αLNNd) that contains the laminin N-terminal (LN) domain of the laminin α1-subunit and the G2-G3 
domains of nidogen, which simultaneously rescued polymerization of mutant truncated laminin α2/
Lm211 (right) and linked laminin to the collagen IV network (not depicted). αLNNd thereby restored 
muscle function in dy2J/dy2J mice.
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able delivery systems and pharmaceutical 
strategies (1), hold promise as future thera-
peutics for congenital muscular dystrophy. 
Importantly, the small sizes of αLNNd (157 
kDa) and mini-agrin (106 kDa) relative 
to the affected 341-kDa LMα2 chain and 
the approximately 750-kDa Lm211 trim-
er, together with the fact that αLNNd and 
mini-agrin function as monomers, make 
them well suited for therapeutic interven-
tion, whether delivered as naked or virally 
encoded proteins.
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of control animals and normalized most 
histopathological parameters. αLNNd 
also normalized mutant LMα2 and LMγ1 
protein levels in vivo to those of control 
mice and restored polymerization of the 
mutant Lm211 on the surface of cultured 
cells, indicating that the fusion protein 
behaved as predicted.
Prospects for the future
There are currently no effective treatments 
for muscular dystrophies. Experimental 
studies reveal that pharmaceutical modu-
lation of some basic physiological and cell 
biological processes, including inflamma-
tion, fibrosis, apoptosis, and regeneration, 
may improve patients’ phenotypes (1). 
In parallel, we summarize here exciting, 
basic science–driven molecular modula-
tions that address the matrix protein defi-
ciencies underlying congenital muscular 
dystrophies. Although McKee et al. did 
not investigate inducible rescue with αLN-
Nd, which would better mimic attempted 
therapy in a clinical context, the efficacy of 
induced expression of mini-agrin (20) indi-
cates that dy2J/dy2J phenotypes would likely 
be improved by late therapeutic interven-
tion. In addition, Qiao et al. demonstrated 
that expression of a mini-agrin cDNA pack-
aged into an adeno-associated virus that 
can either be directly injected into mus-
cles or delivered systemically improves 
phenotypes in mice (21). Interestingly, 
αLNNd did not interfere with WT Lm111 
polymerization in assays on myotubes in 
vitro (11), suggesting that this fusion pro-
tein does not perturb normal BM integrity 
in vivo. We would further suggest that the 
combination of mini-agrin and αLNNd 
may have synergistic effects by enhancing 
dystroglycan binding of an αLNNd-stabi-
lized LMα4 network, the most highly com-
pensating laminin in patients and mice 
lacking LMα2. The study by Mckee et al. 
indicates that functional designer mole-
cules, potentially in combination with suit-
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